Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD.
Fozard
J R
JR
Novartis Pharma AG, WSJ-386.508, Basel, CH-4002, Switzerland.
Hannon
J P
JP
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000503:physiopathology; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000378:metabolism*; D013806:Theophylline / Q000494:pharmacology / Q000627:therapeutic use; D014970:Xanthines / Q000494:pharmacology / Q000627:therapeutic use
D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D008024:Ligands; D018047:Receptors, Purinergic P1; D014970:Xanthines; D013806:Theophylline; C034347:enprofylline